Page 2 1 Todos los derechos reservados Rev. Chil. Psiquiatr ...

sion in adolescents at ultra-high riskfor psychosis. Schizophr Res. 2011,126: 58–64.8. McGorry P, Nelson B, Amminger P,Bechdolf A, Francey S, Berger G, et al.Intervention in Individuals at Ultra-High Risk for Psychosis: A Review andFuture Directions. J Clin Psychiatry2009, 70(9):1206–1212.9. Algon S, Yi J, Calkins M, Kohler C,Borgmann-Winter K. Evaluation andTreatment of Children and AdolescentsWith Psychotic Symptoms. CurrPsychiatry Rep. 2012, 14:101–110.10. Brummitt K, Addington J. Treatmentpossibilities for individuals at clinicalhigh risk of psychosis. Early IntervPsychiatry. 2012, 1-7.11. Lencz T, Smith C, McLaughlin D,Auther A, Nakayama E, Hovey L,Cornblatt B. Generalized and SpecificNeurocognitive Deficits in ProdromalSchizophrenia. Biol psychiatry. 2006,59:863–871.12. Fusar-Poli P, Borgwardt S, BechdolfA, Addington J, Riecher-Rossler A,Schultze-Lutter F, et al. The PsychosisHigh-Risk State. A ComprehensiveState of the Art Review. Arch Gen Psychiatry.2012, 19: 1-14.13. Takahashi T, Wood S, Yung A, SoulsbyB, McGorry P, Suzuki M, et al. ProgressiveGray Matter Reduction ofthe Superior Temporal Gyrus DuringTransition to Psychosis. Arch Gen Psychiatry.2009, 66(4): 366-376.14. Carletti F, Woolley J, Bhattacharyya S,Pérez-Iglesias R, Fusar Poli P, ValmaggiaL, et al. Alterations in White MatterEvident Before the Onset of Psychosis.Schizophr Bull. 2012, 38(6): 1170-1179.15. Liu P, Parker A, Hetrick S, Callahan P,de Silva S, Purcell R. An evidence mapof interventions across premorbid, ultra-highrisk and first episode phasesof psychosis. Schizophr Res. 2010, 123:37–44.16. Johannessen J, Larsen T, Joa I, Melle I,Friis S, Opjordsmoen S, et al. Pathwaysto care for first-episode psychosis in anearly detection healthcare sector : Partof the Scandinavian TIPS study. Br JPsychiatry. 2005, 187 (48): 24-28.17. Preti A, Cella M. Randomized-controlledtrials in people at ultra high riskof psychosis: A review of treatmenteffectiveness. Schizophr Res. 2010,123:30–36.18. Francey S, Nelson B, Thompson A,Parker A, Kerr M, Macneil C, et al.Who needs antipsychotic medicationin the earliest stages of psychosis? Areconsideration of benefits, risks, neurobiologyand ethics in the era of earlyintervention. Schizophr Res. 2010,119: 1–10.19. Yung A, McGorry P. Prediction of psychosis:setting the stage. Br J Psychiatry.2007, 191(51):1-8.20. McGorry P, Nelson B, Amminger P,Bechdolf A, Francey S, Berger G, et al.Intervention in Individuals at Ultra-High Risk for Psychosis: A Review andFuture Directions. J Clin Psychiatry2009, 70(9):1206–1212.21. Vallina O, Lemos S, Fernández P. Estadoactual de la detección e intervencióntemprana en psicosis. Apuntes dePsicología. 2006, 24(1-3):185-22122. McGorry P, Yung A, Phillips L, PanYuen H, Francey S, Cosgrave E, et al.Randomized Controlled Trial of InterventionsDesigned to Reduce theRisk of Progression to First-EpisodePsychosis in a Clinical Sample WithSubthreshold Symptoms. Arch GenPsychiatry. 2002, 59:921-928.23. McGlashan T, Zipursky H, Perkins D.,Addington J, Miller T, Woods S, et al.Randomized, double- blind trial ofolanzapine versus placebo in patientsprodromally symptomatic for psychosis.Am J Psychiatry. 2006, 163 (5):790–799.24. McGlashan T, Zipursky H, Perkins D.,Addington J, Miller T, Woods S, et al.The PRIME North America randomizeddouble-blind clinical trial of olanzapineversus placebo in patients atrisk of being prodromally symptomaticfor psychosis. I. Study rationale anddesign. Schizophr Res. 2003, 61: 7–18.25. Amminger P, Schäfer M, Papageor-Todos los derechos reservados Rev. Chil. Psiquiatr. Neurol. Infanc. Adolesc. / Volumen 24, Nº 1, Marzo 201341